 relationship chemotherapeutic endocrine intervention natural killer cell activity human breast cancer Peripheral natural killer NK activity target tumor cells patients breast cancer treatment combination chemotherapy and/or endocrine therapy NK activity untreated Stage patients evidence disease healthy controls NK activity individuals cytotoxic drug therapy reduction lymphocyte recoveries chemotherapeutic intervention Lymphocyte counts calculation absolute NK activity significant reduction NK activity patients localized systemic disease chemotherapy Different chemotherapeutic agents NK activity Stage II patients phenylalanine mustard PF cyclophosphamide /methotrexate CMF showed significant reductions overall NK activity relative healthy controls Stage patients ned Patients P/doxorubicin /F/tamoxifen Tx PAFT reduced NK activity relative patients Patients short-dose C/A CA protocol normal levels overall NK activity High-risk Stage patients methotrexate /F MF sequential leucovorin rescue patients metastatic disease endocrine therapy Tx acetate Meg overall NK activities range healthy controls Patients systemic disease CMF CMF/vincristine/prednisone CMFVP vinblastine/A/thiotepa/fluoxymesterone VATH mitomycin/mitoxantrone MtMx regimens overall levels absolute NK healthy controls metastatic patients endocrine therapy NK cytolytic data multiple effector ratios exponential regression analysis elevation NK cell responses Stage patients ned decline NK cell responses cytotoxic chemotherapy due alterations maximal plateau levels NK cell cytotoxicity asymptote values values regression analysis indices relative killing capacities individual NK cells unaltered populations results cytolytic lymphocyte NK pool Stage patients cancer result cytotoxic therapy